>> ``We are extremely pleased with the progress of our MIDAS platform technology,'' said
Perry B. Molinoff, M.D., executive vice president of research and development for Palatin.
``MIDAS has many potential utilities, including drug development related to targets derived
from genomics/proteomics research. We are successfully extending this approach to new internally selected targets and now to
targets of interest with an alliance partner. Internally the MIDAS technology has played a key role in our melanocortin program,
allowing us to generate receptor subtype selective molecules. Several of these compounds are now in preclinical development
for the treatment of sexual dysfunction, OBESITY and inflammation.'' <<
October, 2001.
Some will remember that ol' Perry was the first savior that Spana and Wills, the paramount/aries guys, hired from big pharma. Given options that vested instantly, he didn't stick around long.
Preclinical development, October, 2001. Fact is, the old p/a guys are -- and have been -- outrageous liars. |
